NYSE:CRM

Salesforce (CRM) Price Target & Analyst Ratings

$190.17

-1.10 (-0.58%)

(As of 08/5/2022 08:48 PM ET)

Add

Compare

Today's Range: $186.28
▼
$191.80
50-Day Range: $159.85
▼
$191.27
52-Week Range: $154.55
▼
$311.75

Volume: 4.09 million shs
Average Volume: 7.36 million shs
Market Capitalization: $189.22 billion

P/E Ratio: 184.63
Dividend Yield: N/A
Price Target: $270.53

Salesforce Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 39 Analyst Ratings

Consensus Analyst Price Target

$270.53
42.25% Upside

High Prediction	$375.00
Average Prediction	$270.53
Low Prediction	$175.00

Type	Current 8/8/21 to 8/8/22	1 Month Ago 7/9/21 to 7/9/22	3 Months Ago 5/10/21 to 5/10/22	1 Year Ago 8/8/20 to 8/8/21
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	34 Buy rating(s)	34 Buy rating(s)	33 Buy rating(s)	27 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$270.53	$271.32	$301.74	$279.81
Predicted Upside	42.25% Upside	27.68% Upside	26.42% Upside	20.59% Upside

Get Salesforce Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRM and its competitors with MarketBeat's FREE daily newsletter.

CRM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Salesforce Stock vs. The Competition

Type	Salesforce	Computer and Technology Companies	S&P 500
Consensus Rating Score	2.92	2.59	2.50
Consensus Rating	Moderate Buy	Buy	Hold
Predicted Upside	42.25% Upside	101.60% Upside	18.64% Upside
News Sentiment Rating	Neutral News	Neutral News	Neutral News
MarketBeat Community Rating	Outperform Votes 3052 86.00% Underperform Votes 497 14.00%	Avg. Outperform Votes 224 67.07% Avg. Underperform Votes 110 32.93%	Avg. Outperform Votes 840 68.74% Avg. Underperform Votes 382 31.26%

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/18/2022	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$250.00 ➝ $220.00	+31.44%
6/17/2022	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Schwartz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$205.00	+25.17%
6/3/2022	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$192.00	+3.83%
6/2/2022	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold	$225.00 ➝ $175.00	-0.61%
6/1/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Bhatia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/1/2022	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$260.00 ➝ $225.00	+40.41%
6/1/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$300.00 ➝ $250.00	+56.02%
6/1/2022	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$300.00 ➝ $260.00	+62.26%
6/1/2022	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$225.00 ➝ $235.00	+46.66%
6/1/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$316.00 ➝ $275.00	+71.62%

6/1/2022	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$300.00 ➝ $250.00	+56.02%
6/1/2022	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$300.00 ➝ $260.00	+62.26%
6/1/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$375.00 ➝ $315.00	+96.58%
6/1/2022	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$208.00 ➝ $218.00	+36.05%
5/23/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brent Thill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$330.00 ➝ $260.00	+61.49%
5/23/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$285.00 ➝ $225.00	+39.75%
5/18/2022	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Baldry Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$242.00	+48.88%
5/18/2022	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$295.00 ➝ $225.00	+37.42%
5/17/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Karl Keirstead Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	NA	$225.00 ➝ $185.00	+12.72%
5/16/2022	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$360.00 ➝ $291.00	+74.35%
5/12/2022	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Positive
5/9/2022	CICC Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
4/25/2022	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$281.00 ➝ $223.00	+30.08%
3/2/2022	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$315.00 ➝ $260.00	+23.45%
3/2/2022	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jaluria Rishi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$325.00	+57.48%
3/2/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rangan Kash Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Buy	$340.00 ➝ $360.00	+74.44%
3/2/2022	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brad Sills Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy	$360.00 ➝ $300.00	+46.67%
3/2/2022	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$315.00 ➝ $275.00	+31.65%
12/12/2021	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$375.00	+40.96%
12/1/2021	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Terry Tillman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$315.00 ➝ $330.00	+25.21%
11/22/2021	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$360.00	+23.53%
9/24/2021	Monness Crespi & Hardt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian White Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sell ➝ Buy	$300.00 ➝ $328.00	+18.05%
9/24/2021	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Patrick Walravens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$320.00 ➝ $325.00	+16.97%
9/14/2021	Nord/LB Subscribe to MarketBeat All Access for the recommendation accuracy rating	Donie Wolfgang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$275.00	+8.12%
8/27/2021	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$290.00 ➝ $321.00	+19.87%
8/26/2021	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$266.00 ➝ $290.00	+5.97%
8/26/2021	FBN Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$290.00 ➝ $310.00	+13.28%
8/26/2021	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$290.00 ➝ $300.00	+9.87%
8/26/2021	KGI Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$330.00	+26.51%
6/28/2021	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy ➝ Buy	$320.00	+32.30%
2/26/2021	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$252.00 ➝ $273.00	+24.09%
12/2/2020	Pritchard Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$300.00 ➝ $250.00	+3.58%
11/17/2020	Smith Barney Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$304.00	+18.93%
6/1/2020	Cfra Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy	$222.00 ➝ $225.00	+28.71%
5/29/2020	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
5/22/2020	SunTrust Banks Subscribe to MarketBeat All Access for the recommendation accuracy rating	Terry Tillman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$210.00	+18.08%
5/4/2020	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sell
2/28/2020	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating	Logan Purk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
2/27/2020	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Positive ➝ Buy	$180.00 ➝ $215.00	+20.20%
12/5/2019	Cross Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Outperform
12/4/2019	Northland Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robert Breza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$185.00	+14.50%
11/13/2019	Piper Jaffray Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$190.00	+16.85%
8/23/2019	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	James Rutherford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Buy	$184.00	+18.61%
8/23/2019	Compass Point Subscribe to MarketBeat All Access for the recommendation accuracy rating	Marshall Senk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Buy	$193.00	+24.41%
8/23/2019	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Eberle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$180.00 ➝ $185.00	+24.80%

(Data available from 8/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Salesforce Price Target - Frequently Asked Questions

What is Salesforce's consensus rating and price target?: According to the issued ratings of 39 analysts in the last year, the consensus rating for Salesforce stock is Moderate Buy based on the current 4 hold ratings, 34 buy ratings and 1 strong buy rating for CRM. The average twelve-month price prediction for Salesforce is $270.53 with a high price target of $375.00 and a low price target of $175.00. Learn more on CRM's analyst rating history.
Do Wall Street analysts like Salesforce more than its competitors?: Analysts like Salesforce more than other Computer and Technology companies. The consensus rating for Salesforce is Moderate Buy while the average consensus rating for computer and technology companies is Buy. Learn more on how CRM compares to other companies.
Do MarketBeat users like Salesforce more than its competitors?: MarketBeat users like Salesforce more than other Computer and Technology companies. 86.00% of MarketBeat users gave Salesforce an outperform vote while computer and technology companies recieve an average of 67.08% outperform votes by MarketBeat users.

Is Salesforce being upgraded or downgraded by Wall Street analysts?: Over the previous 90 days, Salesforce's stock had 1 upgrade and 1 downgrade by analysts.
Does Salesforce's stock price have much upside?: According to analysts, Salesforce's stock has a predicted upside of 27.20% based on their 12-month price targets.
What analysts cover Salesforce?: Salesforce has been rated by Barclays, BMO Capital Markets, Citigroup, Cowen, Cowen, Credit Suisse Group, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., Loop Capital, Mizuho, Morgan Stanley, Oppenheimer, OTR Global, Piper Sandler, Raymond James, Robert W. Baird, Roth Capital, Stifel Nicolaus, UBS Group, Wells Fargo & Company, and William Blair in the past 90 days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

This page (NYSE:CRM) was last updated on 8/8/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here